Effects of different trainings on nonverbal expressiveness and assertiveness

Die vorliegende Untersuchung vergleicht die Wirkung zweier verschiedener Trainings auf nichtverbale Ausdruckskraft und Selbstsicherheit. Die Ergebnisse zeigen, daß aufgrund eines Verhaltenstrainings die nichtverbale Expressivität der Trainierenden signifikant gesteigert werden kann. Ein Selbstsicherheitstraining hat hier nur geringe Effekte. Das Verhaltenstraining bewirkt eine Erhöhung der fremdwahrgenommenen, das Selbstsicherheitstraining eine Erhöhung der selbstwahrgenommenen Selbstsicherheit. Zwischen fremdwahrgenommener Selbstsicherheit und nichtverbalem Verhalten zeigt sich ein mittlerer linearer Zusammenhang. (DIPF/Orig.)This study compares the effects of two different trainings on nonverbal expressiveness and assertiveness. The results indicate that nonverbal expressiveness of the trainees can be increased significantly through a training program, an assertivenes training has only minimal effects. The nonverbal behavior training causes an increase in observer attributed assertiveness, the assertiveness training an increase in self-attributed assertiveness. There is a medium linear correlation between observer attributed assertiveness and nonverbal behavior

Evaluation of a Training Program for Nonverbal Sensitivity and Expressiveness

Eine experimentelle Untersuchung wurde durchgeführt, um die Wirkung eines Trainingsprogramms auf die nichtverbale Wahrnehmungs- und Ausdrucksfähigkeit in den Bereichen Stimme, Augen, Blickkontakt, Mimik, Gestik und Körperhaltung und -bewegung sowie auf die Klarheit und Interessantheit von Kurzvorträgen zu prüfen. Die Ergebnisse zeigen, daß sich nichtverbale Wahrnehmungs- und Ausdrucksfähigkeit durch Training signifikant steigern läßt und daß eine Steigerung nichtverbaler Expressivität mit einer Steigerung der Klarheit und Interessantheit von Vorträgen einhergeht. (DIPF/Orig.)An experimental study was conducted to test the effects of a training program on nonverbal sensitivity and expressive nonverbal behavior (vocal delivery, eyes, eye contact, facial expressions, gesturing, and body movement) as well as on clarity and degree of interest of short presentations. The results indicate that expressive nonverbal behavior is trainable and that an increase in nonverbal sensitivity and in the level of nonverbal expressiveness causes an increase in the clarity and degree of interest of the presentations

The training of nonverbal expressiveness and its gender-specific relationship with persuasiveness

Eine neue attributionstheoretische Sichtweise des Überzeugungsprozesses steht neben der „klassischen“ Betrachtungsweise (Einstellungsänderungsprozesse) und wird mit nichtverbalem Verhalten in Verbindung gebracht. Diese Untersuchung zeigt, daß sich nichtverbale Expressivität durch einen Trainingskurs erhöhen läßt. Gleichzeitig wächst die selbst- und die fremdattribuierte Überzeugungskraft eines Senders an. Nur für Männer besteht ein mittlerer positiver Zusammenhang zwischen Überzeugungskraft und nichtverbaler Expressivität und zwischen selbst- und fremdattribuierter Überzeugungskraft. (DIPF/Orig.)The view of persuasiveness as an attribution process is compared to the “classical” type of research (attitude change). It is related to nonverbal behavior. This study shows that the level of nonverbal expressiveness can be increased through a training program. Self-attributions and observer ratings of persuasiveness are improved simultaneously. There is a medium positive correlation for male subjects only between persuasiveness and nonverbal expressiveness and between self- and observer attributed persuasiveness

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8; 21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, similar to 40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21)

Core-binding factor acute myeloid leukemia with t(8;21) Risk factors and a novel scoring system (I-CBFit)

Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21) (q22;q22). Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median diseasefree (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P <0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P <0.0001). Conclusions: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk score)

Comparative Study of the Osteogenic Differentiation Potential of Adipose Tissue-Derived Stromal Cells and Dedifferentiated Adipose Cells of the Same Tissue Origin under Pro and Antioxidant Conditions

Adipose tissue-derived stromal cells (ASCs) play an important role in various therapeutic approaches to bone regeneration. However, such applications become challenging when the obtained cells show a functional disorder, e.g., an impaired osteogenic differentiation potential (ODP). In addition to ASCs, human adipose tissue is also a source for another cell type with therapeutic potential, the dedifferentiated fat cells (DFATs), which can be obtained from mature adipocytes. Here, we for the first time compared the ODPs of each donors ASC and DFAT obtained from the same adipose tissue sample as well as the role of oxidative stress or antioxidative catalase on their osteogenic outcome. Osteogenic potential of ASC and DFAT from nine human donors were compared in vitro. Flow cytometry, staining for calcium accumulation with alizarin red, alkaline phosphatase assay and Western blots were used over an osteogenic induction period of up to 14 days. H2O2 was used to induce oxidative stress and catalase was used as an antioxidative measure. We have found that ASC and DFAT cultures&rsquo; ODPs are nearly identical. If ASCs from an adipose tissue sample showed good or bad ODP, so did the corresponding DFAT cultures. The inter-individual variability of the donor ODPs was immense with a maximum factor of about 20 and correlated neither with the age nor the sex of the donors of the adipose tissue. Oxidative stress in the form of exogenously added H2O2 led to a significant ODP decrease in both cell types, with this ODP decrease being significantly lower in DFAT cultures than in the corresponding ASC cultures. Regardless of the individual cell culture-specific ODP, however, exogenously applied catalase led to an approx. 2.5-fold increase in osteogenesis in the ASC and DFAT cultures. Catalase appears to be a potent pro-osteogenic factor, at least in vitro. A new finding that points to innovative strategies and therapeutic approaches in bone regeneration. Furthermore, our results show that DFATs behave similarly to ASCs of the same adipose tissue sample with respect to ODPs and could therefore be a very attractive and readily available source of multipotent stem cells in bone regenerative therapies

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

BackgroundAlthough the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P &lt; 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P &lt; 0.0001).ConclusionsI-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score)

Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/166221/1/ijlh13338.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/166221/2/ijlh13338_am.pd